Developer docs
API playgroundTry for free, no card

Search company profiles

Phlecs

Full company profile

uuid002liyb

Namestring
Phlecs
Legal namestring
Phlecs BV
Websiteurl
phlecs.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Phlecs BV is a Dutch medical-technology company, founded in April 2019 in Eindhoven as a spin-out of Philips Healthcare's Light & Health unit by four former Philips employees with deep photo-dermatology expertise. The company develops a UV-free, drug-free full-body blue LED phototherapy platform operating at a 453nm wavelength that deactivates inflammatory immune cells (T-cells, dendritic cells), reduces keratinocyte hyperproliferation, and counteracts the itch-scratch cycle in conditions such as atopic dermatitis, psoriasis, and chronic pruritus. Clinical evidence includes 40-50% improvement in eczema symptoms and quality of life after ten treatments, a 96% increase in serotonin levels, and a 150-patient prospective study demonstrating non-inferiority of blue LED therapy to both UVB narrow band and UVA1.

Phlecs's commercial product is the Full Body Blue Light Professional device, a CE marked Class IIa medical device built on a Quality Management System certified to ISO 13485:2016, currently sold directly to dermatology clinics in Poland, Germany, and Denmark. The company's second product, the Full Body Home Connected device, is a patented, portable, foldable, app-connected home unit with a personalized treatment algorithm and is being developed through an OP-Zuid-funded consortium; it is planned for U.S. launch in 2027 and European launch in 2028. The company is headquartered in Vlissingen, with an R&D presence in Terneuzen and a founding office in Eindhoven, and operates with a 1-10 person team.

The business model is currently B2B hardware sales of a single professional device SKU to dermatology clinics across Europe, with a planned transition to a hybrid B2B-plus-direct-to-consumer model once the home device launches. To date, Phlecs has financed operations primarily through non-dilutive grants — €1,000,000 from OP-Zuid (May 2025), €50,000 from Metropoolregio Eindhoven (2021), and EIT Health Bridgehead support (2020, 2022) — plus an undisclosed founding round with private investors in May 2019; no institutional venture capital rounds are disclosed. Go-to-market relies on direct enterprise field sales in three EU countries, clinical publication and conference presence (German Dermatology Congress, International Congress of Atopic Dermatitis, Ageing Fit), and the EIT Health network for cross-border scaling.

Short descriptiontext

Phlecs BV is a Dutch MedTech spin-out of Philips Healthcare that develops and commercializes a CE marked Class IIa, UV-free full-body 453nm blue LED phototherapy device for treating inflammatory skin conditions such as atopic dermatitis, selling to dermatology clinics across Europe and developing a connected home-use device for 2027-2028 launch.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersEindhoven, Netherlands
HQ citystring
Eindhoven
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
blue LED phototherapy, medical device manufacturing, inflammatory skin treatment, atopic dermatitis therapy, UV-free dermatology devices
Industry3 codes
PRIMARYHSALADAJ
LED Light Therapy Treatments
SECONDARYCRABAKAI
Skincare Devices (Cleansing Brushes, Microcurrent, LED, Dermaplaning)
SECONDARYCRABAAAJ
Skincare Devices & Beauty Tech (LED, Microcurrent, Cleansing Devices)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Medical Phototherapy Devices
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Medical Device Sales - Professional
TypeHardware Sales
Description

Sale of CE certified Class IIa Full Body Blue Light professional devices to dermatology clinics across Europe.

phlecs.com
2Medical Device Sales - Home Use
TypeHardware Sales
Description

Sale of next-generation home-connected full body blue light devices for personal use. Launch planned for US in 2027 and Europe in 2028.

phlecs.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Phlecs develops and sells a proprietary full-body blue LED phototherapy platform using 453nm wavelength LEDs to treat inflammatory skin conditions such as atopic dermatitis, eczema, psoriasis, and chronic pruritus without UV radiation or drugs. The company sells a CE-marked Class IIa Full Body Professional device to dermatology clinics in Europe and is developing a Full Body Home Connected device for at-home personalized treatment, scheduled for US launch in 2027 and Europe in 2028.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 40-50% improvement in eczema symptoms, itching, and overall quality of life after 10 blue light treatments
+6 more records
Product overview1 text field

Phlecs offers a proprietary full-body Blue LED Therapy platform using 453nm wavelength LEDs for treating inflammatory skin conditions without UV radiation or drugs. The portfolio consists of two main devices: the Full Body Professional (currently CE Mark Class IIa certified and available for dermatology clinics in Europe) and the Full Body Home Connected (personalized home-use device with algorithm-driven parameter adjustment and connected monitoring app, launching 2027-2028). Both products leverage over 15 years of clinical research originating from Philips Healthcare.

Product and service2 records
1Phlecs Blue LED Therapy – Full Body Professional
CategoryMedical Phototherapy Device - Professional
Description

A UV-free, drug-free, CE Mark Class IIa medical device for dermatology clinics in Europe, utilizing 453nm high-intensity clinical-grade blue LEDs with auto-timing treatment duration of 15 minutes per body side. Currently available in Poland, Germany, and Denmark.

2Phlecs Blue LED Therapy – Full Body Home Connected
CategoryMedical Phototherapy Device - Home Use
Description

A UV-free, drug-free personalized home-use blue LED therapy device that uses an algorithm to adjust light parameters based on patient condition. Features portable/foldable design, connected monitoring with app, and patient adherence tracking. Expected U.S. launch in 2027 and European launch in 2028.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2022-01-01
Description

Selected for EIT Health Bridgehead Europe programme 2022 to support sales expansion in Germany. EIT Health is a European health innovation network.

Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2020-01-01
Description

Winner of EIT Health Bridgehead Global programme 2020 following CE marking of Full Body Blue Light device. Provided support for US market introduction.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Unitron Systems (IJzendijke) is responsible for development of the connected home device as part of the OP-Zuid consortium. Provides device engineering expertise.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

DermaTeam (Middelburg) manages clinical and product validation for the home device development consortium.

5Customer Innovation Center
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Customer Innovation Center (Roosendaal) guides implementation of home device into the healthcare system.

phlecs.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Poland's largest public medical university conducted clinical studies on full-body blue light therapy for eczema and post-COVID chronic fatigue, confirming treatment effectiveness.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers8 records
1Solarc Systems
TypeDirect peer
Description

Solarc Systems manufactures UV phototherapy devices for psoriasis, eczema, and vitiligo, including home-use units. It is comparable to Phlecs as a phototherapy hardware specialist serving both clinic and home segments, though focused on UV rather than blue LED technology.

TypeDirect peer
Description

Daavlin is a US-based manufacturer of phototherapy equipment for dermatological conditions including psoriasis, eczema, and vitiligo. It is a direct competitor to Phlecs's professional device, offering full-body UV and UVA/UVB phototherapy systems to dermatology clinics—the same customer segment Phlecs targets. Daavlin is the incumbent whose UV-based products would be displaced by the EU fluorescent lamp ban.

TypeBroad incumbent
Description

Signify is the spin-out parent lineage of Phlecs (via Philips Light & Health) and a global lighting giant. While Signify's core business is general lighting, it historically participated in medical phototherapy and UV lamp manufacturing—the very category being banned in the EU. Phlecs essentially represents a specialized continuation of this legacy within dermatology.

TypeDirect peer
Description

UVBioTek is a smaller phototherapy equipment manufacturer producing UV phototherapy units for clinical and home use in dermatology. It competes with Phlecs in the narrow-band UVB segment and represents a peer in terms of business model (hardware sales to dermatology clinics and patients).

TypeBroad incumbent
Description

Lumenis is a global leader in energy-based medical aesthetic and dermatology devices, including light-based therapies. While broader and more aesthetic-focused than Phlecs, it competes in adjacent light-based dermatology applications and represents a broader incumbent in the dermatology device space.

TypeEmerging player
Description

Biofrontera is a smaller dermatology-focused biopharmaceutical company specializing in photodynamic therapy and skin disease treatments. It is an emerging peer in the dermatology space, though more pharma-oriented than Phlecs's hardware-only approach.

TypeDirect peer
Description

Waldmann is a German-engineered manufacturer of medical phototherapy devices (UVA/UVB) widely used in European dermatology clinics for treating psoriasis and atopic dermatitis. It is one of Phlecs's closest direct competitors in the European dermatology clinic channel, and is among the incumbents affected by the EU UV lamp ban.

TypeBroad incumbent
Description

STRATA Skin Sciences is a publicly-traded medical dermatology device company with phototherapy and imaging products sold to dermatology clinics. It is a broader incumbent in the dermatology device space with overlapping customer relationships and a more diversified product portfolio than Phlecs.

Market position
Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Phlecs

Medical Phototherapy Devicesphlecs.com

Phlecs BV is a Dutch MedTech spin-out of Philips Healthcare that develops and commercializes a CE marked Class IIa, UV-free full-body 453nm blue LED phototherapy device for treating inflammatory skin conditions such as atopic dermatitis, selling to dermatology clinics across Europe and developing a connected home-use device for 2027-2028 launch.

What Phlecs does

Phlecs BV is a Dutch medical-technology company, founded in April 2019 in Eindhoven as a spin-out of Philips Healthcare's Light & Health unit by four former Philips employees with deep photo-dermatology expertise. The company develops a UV-free, drug-free full-body blue LED phototherapy platform operating at a 453nm wavelength that deactivates inflammatory immune cells (T-cells, dendritic cells), reduces keratinocyte hyperproliferation, and counteracts the itch-scratch cycle in conditions such as atopic dermatitis, psoriasis, and chronic pruritus. Clinical evidence includes 40-50% improvement in eczema symptoms and quality of life after ten treatments, a 96% increase in serotonin levels, and a 150-patient prospective study demonstrating non-inferiority of blue LED therapy to both UVB narrow band and UVA1.

Phlecs's commercial product is the Full Body Blue Light Professional device, a CE marked Class IIa medical device built on a Quality Management System certified to ISO 13485:2016, currently sold directly to dermatology clinics in Poland, Germany, and Denmark. The company's second product, the Full Body Home Connected device, is a patented, portable, foldable, app-connected home unit with a personalized treatment algorithm and is being developed through an OP-Zuid-funded consortium; it is planned for U.S. launch in 2027 and European launch in 2028. The company is headquartered in Vlissingen, with an R&D presence in Terneuzen and a founding office in Eindhoven, and operates with a 1-10 person team.

The business model is currently B2B hardware sales of a single professional device SKU to dermatology clinics across Europe, with a planned transition to a hybrid B2B-plus-direct-to-consumer model once the home device launches. To date, Phlecs has financed operations primarily through non-dilutive grants — €1,000,000 from OP-Zuid (May 2025), €50,000 from Metropoolregio Eindhoven (2021), and EIT Health Bridgehead support (2020, 2022) — plus an undisclosed founding round with private investors in May 2019; no institutional venture capital rounds are disclosed. Go-to-market relies on direct enterprise field sales in three EU countries, clinical publication and conference presence (German Dermatology Congress, International Congress of Atopic Dermatitis, Ageing Fit), and the EIT Health network for cross-border scaling.

Phlecs firmographics

Firmographics
Name
Phlecs
Legal name
Phlecs BV
Website
https://phlecs.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
Phlecs BV is a Dutch MedTech spin-out of Philips Healthcare that develops and commercializes a CE marked Class IIa, UV-free full-body 453nm blue LED phototherapy device for treating inflammatory skin conditions such as atopic dermatitis, selling to dermatology clinics across Europe and developing a connected home-use device for 2027-2028 launch.
Ownership category
akta.pro rank

Phlecs industry classification

Industry
Product category
Medical Phototherapy Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHSALADAJ
LED Light Therapy Treatments
SECONDARYCRABAKAI
Skincare Devices (Cleansing Brushes, Microcurrent, LED, Dermaplaning)
SECONDARYCRABAAAJ
Skincare Devices & Beauty Tech (LED, Microcurrent, Cleansing Devices)

Keywords

  • Blue LED phototherapy
  • Medical device manufacturing
  • Inflammatory skin treatment
  • Atopic dermatitis therapy
  • UV-free dermatology devices

Where Phlecs is headquartered

Location

Headquarters

HQ city
Eindhoven
HQ country
Netherlands
HQ region
Europe

Offices3 records

Markets served

Phlecs business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Medical Device Sales - Professional: Sale of CE certified Class IIa Full Body Blue Light professional devices to dermatology clinics across Europe.
  2. Medical Device Sales - Home Use: Sale of next-generation home-connected full body blue light devices for personal use. Launch planned for US in 2027 and Europe in 2028.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Phlecs product offering

Product offering

Core offering

Phlecs develops and sells a proprietary full-body blue LED phototherapy platform using 453nm wavelength LEDs to treat inflammatory skin conditions such as atopic dermatitis, eczema, psoriasis, and chronic pruritus without UV radiation or drugs. The company sells a CE-marked Class IIa Full Body Professional device to dermatology clinics in Europe and is developing a Full Body Home Connected device for at-home personalized treatment, scheduled for US launch in 2027 and Europe in 2028.

Product overview

Phlecs offers a proprietary full-body Blue LED Therapy platform using 453nm wavelength LEDs for treating inflammatory skin conditions without UV radiation or drugs. The portfolio consists of two main devices: the Full Body Professional (currently CE Mark Class IIa certified and available for dermatology clinics in Europe) and the Full Body Home Connected (personalized home-use device with algorithm-driven parameter adjustment and connected monitoring app, launching 2027-2028). Both products leverage over 15 years of clinical research originating from Philips Healthcare.

Differentiator

Problem solved

Functional benefit

Products and services

  • Phlecs Blue LED Therapy – Full Body Professional A UV-free, drug-free, CE Mark Class IIa medical device for dermatology clinics in Europe, utilizing 453nm high-intensity clinical-grade blue LEDs with auto-timing treatment duration of 15 minutes per body side. Currently available in Poland, Germany, and Denmark.
  • Phlecs Blue LED Therapy – Full Body Home Connected A UV-free, drug-free personalized home-use blue LED therapy device that uses an algorithm to adjust light parameters based on patient condition. Features portable/foldable design, connected monitoring with app, and patient adherence tracking. Expected U.S. launch in 2027 and European launch in 2028.

Quantifiable outcome

  • 40-50% improvement in eczema symptoms, itching, and overall quality of life after 10 blue light treatments
  • +6 more outcomes

Companies that use Phlecs

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Phlecs technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Phlecs partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core.

  • EIT HealthcoreGTM or Marketing Partner · 1 January 2022Selected for EIT Health Bridgehead Europe programme 2022 to support sales expansion in Germany. EIT Health is a European health innovation network.
  • EIT HealthcoreGTM or Marketing Partner · 1 January 2020Winner of EIT Health Bridgehead Global programme 2020 following CE marking of Full Body Blue Light device. Provided support for US market introduction.
  • Unitron SystemscoreStrategic or Co-development PartnerUnitron Systems (IJzendijke) is responsible for development of the connected home device as part of the OP-Zuid consortium. Provides device engineering expertise.
  • DermaTeamcoreStrategic or Co-development PartnerDermaTeam (Middelburg) manages clinical and product validation for the home device development consortium.
  • Customer Innovation CentercoreStrategic or Co-development PartnerCustomer Innovation Center (Roosendaal) guides implementation of home device into the healthcare system.
  • Medical University of ŁódźcoreStrategic or Co-development PartnerPoland's largest public medical university conducted clinical studies on full-body blue light therapy for eczema and post-COVID chronic fatigue, confirming treatment effectiveness.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Phlecs competitors and assessment

Company assessment

Direct peers

  • Solarc Systems: Solarc Systems manufactures UV phototherapy devices for psoriasis, eczema, and vitiligo, including home-use units. It is comparable to Phlecs as a phototherapy hardware specialist serving both clinic and home segments, though focused on UV rather than blue LED technology.
  • Daavlin: Daavlin is a US-based manufacturer of phototherapy equipment for dermatological conditions including psoriasis, eczema, and vitiligo. It is a direct competitor to Phlecs's professional device, offering full-body UV and UVA/UVB phototherapy systems to dermatology clinics—the same customer segment Phlecs targets. Daavlin is the incumbent whose UV-based products would be displaced by the EU fluorescent lamp ban.
  • UVBioTek: UVBioTek is a smaller phototherapy equipment manufacturer producing UV phototherapy units for clinical and home use in dermatology. It competes with Phlecs in the narrow-band UVB segment and represents a peer in terms of business model (hardware sales to dermatology clinics and patients).
  • Waldmann (Herbert Waldmann GmbH): Waldmann is a German-engineered manufacturer of medical phototherapy devices (UVA/UVB) widely used in European dermatology clinics for treating psoriasis and atopic dermatitis. It is one of Phlecs's closest direct competitors in the European dermatology clinic channel, and is among the incumbents affected by the EU UV lamp ban.

Broad incumbents

  • Signify (Philips Lighting): Signify is the spin-out parent lineage of Phlecs (via Philips Light & Health) and a global lighting giant. While Signify's core business is general lighting, it historically participated in medical phototherapy and UV lamp manufacturing—the very category being banned in the EU. Phlecs essentially represents a specialized continuation of this legacy within dermatology.
  • Lumenis: Lumenis is a global leader in energy-based medical aesthetic and dermatology devices, including light-based therapies. While broader and more aesthetic-focused than Phlecs, it competes in adjacent light-based dermatology applications and represents a broader incumbent in the dermatology device space.
  • STRATA Skin Sciences: STRATA Skin Sciences is a publicly-traded medical dermatology device company with phototherapy and imaging products sold to dermatology clinics. It is a broader incumbent in the dermatology device space with overlapping customer relationships and a more diversified product portfolio than Phlecs.

Emerging players

  • Biofrontera: Biofrontera is a smaller dermatology-focused biopharmaceutical company specializing in photodynamic therapy and skin disease treatments. It is an emerging peer in the dermatology space, though more pharma-oriented than Phlecs's hardware-only approach.

Market position

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Phlecs social profiles

Digital presence

Phlecs compliance and trust

Trust signal

Compliance2 records

Phlecs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Phlecs leadership team

Management profile

Number of profiles

Profiles5 records

Phlecs funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Phlecs M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Phlecs

What does Phlecs do?

Phlecs develops and sells a proprietary full-body blue LED phototherapy platform using 453nm wavelength LEDs to treat inflammatory skin conditions such as atopic dermatitis, eczema, psoriasis, and chronic pruritus without UV radiation or drugs. The company sells a CE-marked Class IIa Full Body Professional device to dermatology clinics in Europe and is developing a Full Body Home Connected device for at-home personalized treatment, scheduled for US launch in 2027 and Europe in 2028.

Is Phlecs a public or private company?

Phlecs is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Phlecs founded?

Phlecs was founded in 2019. It employs 1 to 10 people.

Where is Phlecs based?

Phlecs is headquartered in Eindhoven, Netherlands, in the Europe region.

How does Phlecs make money?

Two revenue lines are on record. Medical Device Sales - Professional is the primary driver. The others are medical Device Sales - Home Use.

Who are Phlecs's main competitors?

Direct peers on record are Solarc Systems, Daavlin, UVBioTek and Waldmann (Herbert Waldmann GmbH). Broad incumbents are Signify (Philips Lighting), Lumenis and STRATA Skin Sciences. Biofrontera is listed as an emerging player.

Does Phlecs have an API?

No public API is recorded for Phlecs.

What industry is Phlecs in?

Phlecs's product category is Medical Phototherapy Devices. Its primary akta.pro industry code is HSALADAJ, LED Light Therapy Treatments, with a secondary code of CRABAKAI, Skincare Devices (Cleansing Brushes, Microcurrent, LED, Dermaplaning). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales